Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

NBIX

Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NBIX
DateTimeSourceHeadlineSymbolCompany
01/23/20254:05PMPR Newswire (US)Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and DeviceNASDAQ:NBIXNeurocrine Biosciences Inc
01/21/20254:05PMPR Newswire (US)Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & MetabolismNASDAQ:NBIXNeurocrine Biosciences Inc
01/17/20254:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
01/15/20254:19PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
01/08/20258:30AMPR Newswire (US)Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & MetabolismNASDAQ:NBIXNeurocrine Biosciences Inc
01/06/20254:01PMPR Newswire (US)Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
01/03/20254:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
12/31/20244:17PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
12/20/20248:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
12/20/20248:00AMPR Newswire (US)Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal HyperplasiaNASDAQ:NBIXNeurocrine Biosciences Inc
12/19/20244:47PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
12/19/20244:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
12/17/20244:29PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
12/13/20246:55PMPR Newswire (US)Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal HyperplasiaNASDAQ:NBIXNeurocrine Biosciences Inc
12/03/20246:52PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
11/29/20241:41PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
11/26/20244:01PMPR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in DecemberNASDAQ:NBIXNeurocrine Biosciences Inc
11/12/20245:58PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
11/07/20247:42PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
11/07/20248:30AMPR Newswire (US)Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
11/05/20244:01PMPR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in NovemberNASDAQ:NBIXNeurocrine Biosciences Inc
11/04/20248:30AMPR Newswire (US)Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
11/04/20248:25AMPR Newswire (US)Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive DyskinesiaNASDAQ:NBIXNeurocrine Biosciences Inc
11/01/20247:52PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
11/01/20248:31AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
10/30/20247:04AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NBIXNeurocrine Biosciences Inc
10/30/20247:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
10/30/20247:00AMPR Newswire (US)Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales GuidanceNASDAQ:NBIXNeurocrine Biosciences Inc
10/11/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
10/09/20244:01PMPR Newswire (US)Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:NBIX

Your Recent History

Delayed Upgrade Clock